Clinical trials: AD-MCI
Mild Cognitive Impairment, Alzheimer Disease
Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical…
- Trial name
- NCT04784416
- Testing
- Active tPBM-2.0, 18F-MK-6240
- Where
- 3 sites in United States
- Volunteers
- 196 people
- Sponsor
- NYU Langone Health
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using [18F]Fluorbetazine…
- Trial name
- NCT07764679
- Testing
- [18F]Fluorbetazine injection
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- HTA Co., Ltd.
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study
Recent studies have identified an association between Alzheimer's Disease (AD) and an expansion of DNA content in the brain (prefrontal cortex).
- Trial name
- SONATAS (NCT07210528)
- Testing
- Emtricitabine (FTC), Descovy® (TAF/FTC)
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
MCI-AD, Early Stage Alzheimer's Disease
Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI
As populations age, Alzheimer's disease (AD) is increasing while disease-modifying drugs remain elusive, making early diagnosis and intervention essential.
- Trial name
- NCT07196592
- Testing
- Olfactory stimulation, Temporal Interference,TI, Olfactory-TI Stimulation
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Yuan Shen
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease.
- Trial name
- NCT02503501
- Testing
- Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- HealthPartners Institute
Alzheimer Disease, Mild Cognitive Impairment
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01518374
- Testing
- Florbetapir F 18
- Where
- 26 sites in United States
- Volunteers
- 1,768 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Cognitive Dysfunction, Dementia, Mild
FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Trial name
- NCT05504811
- Testing
- FitMi AD, Conventional exercise program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Alzheimers Disease
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 1 (NCT07169578)
- Testing
- Trontinemab
- Where
- 142 sites in United States, Argentina and 11 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
PET Changes in Alzheimer's Disease (AD)
The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimer's disease using positron emission tomography (PET) to monitor brain glucose metabolism.
- Trial name
- NCT00094913
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Mild Cognitive Impairment, Alzheimer's Disease(AD)
Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and…
- Trial name
- NCT07239310
- Testing
- Participants receive Neuclare Device while continuing their cognitive medication
- Where
- 7 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- Deepsonbio
Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease
This project aims to longitudinally profile plasma-derived GDEVs and plasma biomarkers of neuroinflammation across three stages of the AD continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's…
- Conditions
- Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease Dementia, Alzheimer's Disease (AD)
- Trial name
- GLEVAD (NCT07803055)
- Testing
- blood sampling
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Demyelinating Disorders, MCI
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple…
- Conditions
- Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis)
- Trial name
- NCT06999434
- Testing
- [ 18F]3F4AP, [18F]MK6240, [11C]PIB
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Yale University
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages.
- Trial name
- NCT01767909
- Testing
- Insulin (Humulin® R U-100)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Southern California